



**Regence BlueCross BlueShield of Oregon • Regence BlueShield
Regence BlueCross BlueShield of Utah • Regence BlueShield of Idaho
Independent licensees of the Blue Cross and Blue Shield Association**

Medication Policy Manual

Policy No: dru179

Topic: Amphetamine-dextroamphetamine ER capsules
Date of Origin: May 8, 2009

Revised/Effective Date: May 8, 2009

Next Review Date: May 2010

IMPORTANT REMINDER

This Medical Policy has been developed through consideration of medical necessity, generally accepted standards of medical practice, and review of medical literature and government approval status.

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control.

The purpose of medical policy is to provide a guide to coverage. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care.

Description

Amphetamine-dextroamphetamine ER capsules are marketed by Shire Pharmaceuticals as Adderall[®] XR and by BARR/TEVA. They are used to treat attention-deficit disorder.

Policy/Criteria

- I.** Most contracts require prior authorization approval of BARR/TEVA's amphetamine-dextroamphetamine ER capsules prior to coverage. Amphetamine-dextroamphetamine ER capsules that are manufactured by BARR/TEVA may be considered medically necessary when Adderall[®] XR has been ineffective, not tolerated or contraindicated.

- II.** Administration, Quantity Limitations, and Authorization Period
 - A.** Regence considers amphetamine-dextroamphetamine ER capsules (BARR/TEVA) to be a self-administered medication.

 - B.** Authorization may be reviewed at least annually to confirm that current medical necessity criteria are met and that the medication is effective.

Position Summary

- Amphetamine-dextroamphetamine ER by BARR/TEVA is not considered a generic medication by Regence.

- Amphetamine-dextroamphetamine ER by BARR/TEVA was not approved as an abbreviated new drug application ("ANDA") by the Food and Drug Administration.
(<http://www.accessdata.fda.gov/scripts/cder/drugsatfda/> and <http://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm>)

- Adderall[®] XR remains the least costly amphetamine-dextroamphetamine ER capsule for Regence members.

Cross References
None

Codes	Number	Description
N/A		